Canada Markets closed

AMRN Jan 2024 10.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
8.800.00 (0.00%)
As of 08:33AM EST. Market open.
Full screen
Previous Close8.80
Open7.15
Bid6.20
Ask9.10
Strike10.00
Expire Date2024-01-19
Day's Range8.80 - 8.80
Contract RangeN/A
Volume2
Open Interest80
  • GlobeNewswire

    Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland

    -- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe -- DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Switzerland’s Swissmedic has granted approval to VAZKEPA (icosapent ethyl). Swissmedic approved VAZKEPA to reduce risk of car

  • Zacks

    Why Amarin (AMRN) Stock Might be a Great Pick

    Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Motley Fool

    Why Amarin Stock Was a Winner Today

    Before market open, Amarin announced that its Vazkepa (brand-named Vascepa in the U.S.) has been approved by Australia's Therapeutic Good Administration (TGA). Amarin didn't hesitate to mention that the Australian nod represents the fifth regulatory approval for Vazkepa/Vascepa. Among these jurisdictions are the U.S. and the European Union, which consists of 27 countries on that continent.